Spectrum Pharmaceuticals Inc. under investigation for potential securities fraud

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.

July 18, 2025

Vol.51 No.28

By Paul Goldberg and Katie Goldberg

Regulatory News

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.

July 18, 2025

Vol.51 No.28

By Jacquelyn Cobb and Sara Willa Ernst

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

NIH says it’s moving away from animal-based models

NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Cancer Policy

Trump threatens tariffs on Big Pharma by Aug. 1

President Trump said he would impose tariffs on pharmaceutical products and semiconductors as soon as Aug. 1.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Cancer Policy

CMS publishes Medicare physician fee schedule proposal

The Centers for Medicare & Medicaid Services published a proposed rule, which it says aligns with Trump’s “Big Beautiful Bill.”

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

Spectrum Pharmaceuticals Inc. under investigation for potential securities fraud

YOU MAY BE INTERESTED IN

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

Imaging’s ride to the bottom in clinical trials—and why it matters now

NIH says it’s moving away from animal-based models

Trump threatens tariffs on Big Pharma by Aug. 1

CMS publishes Medicare physician fee schedule proposal

Renew today!

Subscriber content

Never miss an issue!

Login

Spectrum Pharmaceuticals Inc. under investigation for potential securities fraud

YOU MAY BE INTERESTED IN

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentumAs oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

Imaging’s ride to the bottom in clinical trials—and why it matters now

NIH says it’s moving away from animal-based models

Trump threatens tariffs on Big Pharma by Aug. 1

CMS publishes Medicare physician fee schedule proposal

Never miss an issue!

Login

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic